The rat α2-C4 adrenergic receptor gene encodes a novel pharmacological subtype  by Voigt, Mark M. et al.
Volume 278, number 1, 45-50 FEBS 09301 January 1991 
0 1991 Federation of European Biochemical Societies 00145793/91/$3.50 
ADONIS 0014579391000188 
The rat a,+4 adrenergic receptor gene encodes a novel pharn-mcological 
subtype 
Mark M. Voigt l**l*, Susan K. McCune2, Robert Y. Kanterman 3A and Christian C. FeldelJ 
1 Laboratory of Molecular Sioiogy, NINDS, 2Laboratory of Developmental Neurobiology. NICHD, 3Laboratory of Cell Biology, 
NIMH, Bethesda, MD 20817, USA and 4Howard Hughes Medical Institute-NIH Research Scholars Program, Bethesda, 
MD 20892, USA 
Received 25 October 1990 
A rat gene and brain cDNA (pA2d) encoding the homologue of the human a-C4 adrenergic receptor subtype were isolated and characterized. 
RNA blots.indicate that this gene is expressed in brain, heart and kidney but not in lung, liver or pancreas. Yohimbine, WB-4101 and prasozin 
all exhibited high affinity for this receptor in binding studies. Clonidine was more potent and efficacious than norepinephrine in inhibiting forskolin- 
stimulated CAMP production in CHO cells expressing pA2d. Together, these data suggest hat the c+C4 gene product defines a previously un- 
described pharmacological subtype of %-adrenergic receptor. 
%-Adrenoreceptor; Gene expression; Gene couplinp; CAMP inhibition 
1. INTRODUCTION the a*~-C2 gene encodes a receptor of the a2B subtype. 
The classification of the ru~-C4 gene product has yet to 
Traditionally, czz-adrenergic receptor activation in be determined. 
brain has been linked to inhibition of adenylate cyclase In order to study the characteristics and functions of 
activity [l]. Recent studies have suggested that cu2-ad- multiple az-adrenergic receptors in the brain, we have 
renergic receptor activation can lead to perturbations of set about to clone the genes and cDNAs ,encoding 
multiple cellular processes in a CAMP-independent members of this receptor family expressed in rat brain. 
manner through coupling with guanine nucleotide bin- In this report the pharmacology and distribution of ex- 
ding proteins (G-proteins). Such events include activa- pression of a rat gene and a cognate cDNA encoding an 
tion of K+ channels [2], alterations in Na*/H’ ex- curadrenergic receptor protein homologous to the 
change that lead to intracellular pH changes 131, and in- human cuz-C4 adrenergic receptor is described. This 
hibition of voltage-dependent Ca2+ channels [41. Xn receptor exhibited binding and functional properties 
keeping with these multiple functions of crz-adrenergic that were dissimilar to those for the pharmacologically 
receptors, pharmacological evidence derived from characterized A, B and C subtypes. The findings 
studies utilizing non-neuronal cell cultures suggests the presented here suggest that the c&Z4 gene product 
existence of multiple LYZ subtypes. A classification defines a pharmacologically novel adrenergic receptor 
scheme defining these subtypes as WA, LYZB and cx2C subtype. 
has been suggested based upon the rank order of poten- 
cies for a large number of antagonists 151. More con- 2. EXPERIMENTAL 
elusive evidence for the existence of multiple a*2 sub- 
types has come from recent molecular cloning experi- 2.1 Isolation of genomic and cDNA clones 
ments which have demo&rated the existence of at least Approximately 12x lo6 recombinants of a hCharon4.4 rat 
three genes encoding a2-adrenergic receptors in the genomic library (Clontech Laboratories, Palo Alto, CA) were screen- 
human designated a~-C2, -C4 and -Cl0 16-81 and of a ed by filter hybridization [ll] in 6x SSC, 10 mM EDTA, 0.1% 
subtype in the rat (RNGruz) homologous to the (u2-C2 sodium pyrophosphate, 0.2% SDS, 100 &ml denatured herring 
[9]. Preliminary evidence suggests that the ~a-Cl0 gene 
sperm DNA at 60°C with two kinased oligonucleotides (Genetic 
Designs, Houston, TX) derived from sequences present in the third 
encodes an adrenergic receptor of the WA subtype and (amino acids 106-122) and fourth (amino acids 161-175) transmem- 
brane domains of the human platelet @I receptor 161. Filters were 
washed in 3xSSC at 65’C and exposed to X-ray film at -70°C. 
Correspondence address: C. Felder, Bldg 36, Rm 3A15, Eight positive clones were identified and one, hgAZd, was chosen for 
LCB/NIMH, Bethesda, MD 20892, USA further study. A rat brain cDNA library in Agtl1 (a gift of Dr Hemin 
Chin, NINDS/NIH) scre’ened with a genomic fragment containing the 
* Present address: Lab. Molecular Neuroendocrinology, ZMBH/ putative receptor coding region from hgA2d yielded six clones. The 
University of Heidelberg, INF-282, D-6900 Heidelberg, Germany largest of the six was 2.8 kb, and contained 900 bp of 5’-untranslated 
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Fig. 1, Restriction map, sequencing strategy and nuclbotide and deduced amino acid sequence for clone hgA2d. (A) Partial restriction map for 
the genomic clone. (B) Map of the X6+ restriction fragment that holds the exon containing the entire coding region of the receptor, The coding 
region is identified by a thickened bar, and the sequencing strategy illustrated by arrows, representing individual13 sequenced clones. under the 
fragment., Nucleotide numbering beings from the first ATG of the coding region of the gene. The star indicates the position of the 5 ‘-terminus 
of the longest CDNA clone obtained, and the poly(A) addition signal is represented by the A+; (C) Nucleotide (above) and deduced amino acid 
(be?owi sequences of the portion of the XbaI fragmqnt containing the coding r.egion of the protein. The untranslated regions of the mRNA are 
in lowercase letters and the assumed translated porti;on of the gene is in uppercase ietters. 
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sequence was extended 3’ to the poly(A) tail and was designated 
AcA2d. Sequenies of all clones were obtained using a chain termina- 
forskolin-stimulated CAMP accumulation in whole cells was perform- 
ed as previously described [1 I]. 
tion protocol with T7 DNA polyrnerase (Sequenase, US 
Biochemicals. USA) and Ml3 vectors as sunnested bv the manufac- 2.3. PJorthern blot analysis _- 
turer. 
2.2. Mammalian cell transfection and radio&and binding studies 
Chinese hamster ovary (CHO) cells and COS-7 cells were Brown as 
previously described [ 1 I]. The cDNA insert from hcA2d was subclon- 
ed into pCDNA-1 (Invitrogen, San Diego, CA) for transient expres- 
sion studies in COS-7 cells, or into pRc/CMV (Invitrogen) for pro- 
duction of stably-transfected cells. COS-7 and CHO cells were 
transfected by calcium phosphate precipitation as previously describ- 
ed [123, with stably-transfected CHO cells selected in medium con- 
taining G418 (500 pg/ml). Clonal cell lines expressing the receptor 
were verified by radioligand binding assays. The COS-7 cell mem- 
branes were prepared 48-72 h after transfection. Membrane prepara- 
tion and radioligand binding using [‘Hlrauwolscine (Amersham, 
Chicago, IL) was performed as previously described [l3]. Clonidine, 
corynanthine, chlorpromazine, epinephrine, norepinephrine and oxy- 
metazoline were from Sigma Chemical Co. (St. Louis, MO), 
prazosin, serotonin, yohimbine and WB-4101 were from Research 
Biochemicals (Natick, MA). Miasurement of the inhibition of 
Total RNA from various tissues was obtained using the guanidine 
,...UW,..,...%. ..#UAY,,, *hi~rv=n~t*-r~cil*m chloride gradient method [lo]. Poly(A) contain- 
ing RNA was then prepared, size-fractionated in formaldehyde- 
containing 1% agarose gels and transferred to Nytran filters 
huell, Keene, NH) [lo]. Blots, probes with 
cRNA synthesized using T7 RNA polymerase 
(Schleicher and SC 
uniformally-labeled 
(Promega, Madison, WI) were hybridized in 6x SSC, 5 x Denhardt’s, 
lOOpg/ml denatured salmon sperm DNA, 2 mM EDTA, 0.2% SDS, 
0.1% NaPPi and 50% formamide at 71DC, washed to a final stringen- 
cy level of 0.5 x SSC/O.S% SDS at 8O’C and X-ray film was then ex- 
posed to the filters at - 70% 
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3. RESULTS AND DISCUSSION 
A restriction map of the 16.4 kb insert of the genomic 
clone hgA2d is shown in Fig. IA. The putative coding 
region was localized to the internal 4.6 kb Xba,I frag- 
ment (Fig. IB), which was then sequenced (Fig. 1C). 
MASpALAAALA+.AAA~GPN S~AGE~GSGG~ANASG~~WGPP~GQYSAGA 
ii 
50 
MASPALAAALAVAAAAGPN SGAGERGSGGVANASGASWGPPRGQYSAGA 50 
f 2 L..- - 
VAGLAAWGFLIVFTWGNVLWIAVLTSRALRAPQNLFLVSLASADILV 100 
VAGLIhAWGFLIVFTWGNVLWIAVLTSRALRAPQNLFLVSLASADILV 100 
L .-p 
3 
XTLVMPFSLANELMAYWYFGQVW RY 150 
ATLVIclpFSLANELMAYWYFGQVWCGVYLALDVLFCTSS~VHLCAISLDRY 150 
WSVTFAVEYNLKRTPR PDGAAYP 200 
WSVTQAVEYNLKRTPR PDGAAYP 200 
5 L 
QCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAK~~RTRTLSEKRGP 
QCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAK~RTRTLSEK~P 
250, 
250 
AGPDGASPTTENGLGKAAGENGHCA PRTEVEPDE 
~GPDGA.S~TTENGLG&~AGEZ~$-~~~ 1 z 
SAAERRR..RRGAL 
R iiP"~~~% &A~R~REEA~G~L 
298 
300 
RRGGRRREGAEGDTGSADGPGpGLAAEQ.GARTASRSPGPGGRLSRASSR 
RRGGRRRiGAEG$iGEADGbG!G&iQ:GAiTASRSp~GGRLSR+SSR 
347, 
350 
I 
SVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAWMGVFVLCWFPFFFS 397 
SVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAWMGVFVLCWFPFFF! 400 
~cREACQI;P~PLFKFFFWIGYCNSSLNPVIYTVFNQDFR~SFKHI 447 b 
YSLYGICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRPSFKHI 450 
LFRRRRRGFRQ 458 
LFRRRRRGFRQ 461 
Fig. 2. Comparison of predicted amino acid sequences for the rat A2D clone and human a~-C4 cDNA. Straight lines indicate conserved amino 
acid changes, while dots indicate non-conserved residues. Amino acid omissions are shown by a period. The putative transmembrane regions are 
delineated by a heavy line and are numbered from I to 7. 
47 
Volume 278, number 1 FEBS LETTERS 
An open reading frame of 1374 bp- was present which 
encoded a 458 amino acid protein with a predicted 
molecular mass of 48900 Da. The sequenGze surfoun- 
ding the initiating methionine codon fits the Kozak con- 
sensus sequerice [14]. During the sequencing of this 
clone a human kidney cDNA encoding an cuz-adrenergic 
receptor, the CUZ-C4, was reported 171. There is a high 
degree of identity, 88% at the predicted amino acid 
level, ,,between clone XgA2d and the, human kidney 
nz-adrenergic receptor (Fig. 2). The few non- 
conservative amino acid substitutions are present in 
aa 
regions of the protein thought not to be involved with 
either ligand binding or effector coupling, such as the 
,amino-terminus region and the middle of the third in- 
tracellular loop [15]. This suggests that AgAZd encodes 
the rat homologue of the human kidney ru~-C4 
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adrenergic receptor. The sequence of the longest brain 
cDNA clone obtained, hcAZd, was co-linear with that 
of the gene, suggesting that this portion of the gene is 
intronless. However, the presence of an intron in the ex- 
tieme §‘-untranslated region cannot be excluded. The 
human a&Z10 adrenergic receptor gene has also been 
reported to the intronless 161. 
Fig. 4. Agonist-induced inhibition of forskolin-stimulated CAMP ac- 
cumulation in CI-IO ceils. Clonidine and norepinephrine inhibited 
forskolin (500 nM)-stimulated CAMP accumulation in CHO cells 
stably expressing the pA2D clone. IC50 for clonidine, 2.8 ktO.15 nM, 
for norepinephrine, 12.5 -+ 0.9 nM, n = 3. Data are the mean& SE of 
triplicate determinations and are representative of at least 3 ex- 
Tissue-specific expression of the rat a&4 adrenergic 
receptor gene is shown in Fig. 3. Two mRNAs, 2.9 and 
2.4 kb, encoding this receptor were found to be most 
abundant in the brain, with lower levels in kidney and 
heart and no detectable signal present in liver, lung or 
pancreas. The weak 4.5,kb band seen in lung was mdst 
likely due to non-specific hybridization to residual 28 S 
rRNA present in the sample. The low signal in heart 
could be due to gene expression in the coronary artery 
endothelium, which has been shown to exhibit CYZ 
receptor-mediated responses (161. As this gene does not 
Fig. 3. RNA blot analysis of rat cu&4 adrenergic receptor expression 
in various rat tissues. Northern blots were prepared and probed as 
dessribed in section 2. Each’ lane contained 5 yp of poly(A)+ RNA 
from the identified tissue. Positions of co-electrophoresed RNA size 
markers (BRL) are shown; : 
In effector-coupling studies of” the expressed rat 
a&!4 receptor cDNA (Fig. 4), the agonists norepine- 
phrine and clonidine inhibited forskolin-stimula’ted 
CAMP accumulation, with clonidine being both more 
potent and more efficacious thari norepitieph’&nC. Both 
agonists could also inhibit prostaglandin E2-stimulated 
CAMP accumulation (data. not shown). These results 
are in direct contrast to those found for the CQB 
adrenergic receptors on NG-1013 cells (personal observa- 
tion and [ 191) and those reported for the cv& adrenergic 
receptor on C?K-1 cells, [IS]: in bbth .cases clonidirie was 
found to have little or no efficaCy or sotency at lhese 
receptors. Clonidine has, hdwever, been reported to 
have agdnist activity at the huinan LYZA (c~C10) r&e@ 
tor. Rndioligand binding studies on the rat ~2-C4 cDNA 
(Fig. 5A,B) demonstrated conclusively that .this recep- 
tor does not belong in the alA adrenergic receptor sub- 
type categofy, as prazosin,,has a higber_affinity than ox- 
ymetazdlink. The calculated Ki v&es of various an- 
tagonists for the rit receptor clone are shown in Table 
48 
: 
periments performed in triplicate. 
appear to be expressed in such highly vascular organs as 
the lung and liver, it suggests that a. different 
Luz-adrenergic receptor subtype gene is expressed in 
these tissues. In order to see rhe signal present in heart 
and kidney it was necessary to expose the blot to X-ray 
film for a length of time that resulted in overexposure 
of the brain mRNA lane. The 2.9 kb signal appears to 
correspond to the cDNA clone isolated. Both the 2.9 
and 2.4 kb species were detected after very stringent 
washing conditions (0.5 x SSC at 9O’C). These findings 
suggest that at least two size classes of transcripts are 
produced from this gene. Based on 3 ‘-genomic se- 
quence, this does not appear to be due to alternative 
polyadenyiation. It is not known whether the two 
species are products of alternative splicing at the 5 ’ -end 
of the transcript or of alternative promotor usage. 
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Fig. 5. [‘HlRauwolscine binding to membrane homogenates from COS-7 cells expressing the pA2d clone. (A) Saturation analysis was carried out 
using [3H]rauwolscine asdescribed in section 2. The concentrations of labeled ligand used spanned the range from 0.05 nM to 10 nM; with non- 
specific binding defined using 100 nM yohimbine. The data from a typical experiment were converted into a Rosenthal plot and are depicted here. 
Data are representative of 3 separate xperiments, with each point in triplicate. (B) Competition curves of various ligands for the receptor from 
a typical experiment are depicted here. Binding was carried out as described in section 2, using 0.5 nM [3H]rauwolscine per assay tube. This experi- 
ment is representative of at least 3 experiments per drug, with each point being performed in triplicate. 
I. To help in comparing ruz-adrenergic receptor subtype 
pharmacology, values from the literature [I $1 gj‘ for the 
azA, alB, and WC, obtained using the same binding 
buffer as this study, are also shown. The rat receptor 
clone exhibits a pharmacological profile similar to that 
of the CYZB and cv$2 adrenergic subtypes, due to the high 
affinity of prazosin and low affinity of oxymetazoline. 
Taken together, the combination of effector-coupling 
and radioligand binding da&suggests strongly that the 
receptor en’coded by the cloned rat cuz-C4 hbmologue 
defines a new pharmacological subtype of adrenergic 
receptor9 one of which prslzosin has high affinity and 
clonidine strong efficacy. 
The findings presented in this report underscore the 
inherent difficulties of performing radioligand binding 
in a complex tissue such as brain. Thus, while past 
studi& hzve used prazosin to unmask the presence of 
‘cwB’ receptors in brain, the results from this pap&r sug- 
gest that at least a portion of these ‘mB’ receptois are 
in fact receptor-encoded by the (r&4 gene. Further 
studies into the sell-type expression and coupling 
mechanisms for this receptor class are needed in order 
to shed more light on its functional significance in 
neural transmission. 
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